Increased incidence of Susac syndrome: a case series study

BMC Neurology

Table 2 Treatment regimens, major side effects and patient outcomes

			Treatment						outcome			Side effects	Maintenece treatment
Patient	Disease Severity	Follwup time (months)	Anti aggregation drugs	IVMP	IVIG	CPM	MMF	RTX	Auditory	Vision	CNS
1	Severe	33	Acetylsalicylic acid (+Clopidogrel)	+	+	+	+	+	Severe bilateral SNHL		No evidence for neurological residual	CMV reactivation	Aspirin, Prednisone, IVIG (1 g/kg), Rituximab,MMF
2	Moderate	33	Acetylsalicylic acid	+	–	+	+	–	SNHL	Bilateral VF deficient	No evidence for neurological residual		Aspirin,MMF
3	Mild	2	Acetylsalicylic acid	+	+	–	+	–	N/A	N/A	N/A	N/A	N/A
4	Moderate	30	Acetylsalicylic acid	+	+	–	+	+		Mild VF deficient	Fatigue	CMV reactivation	Aspirin, IVIG (1 g/kg), Rituximab
5	Severe	30	Acetylsalicylic acid	+	+	+	Azathioprine	+	SNHL	bilateral VF deficient	No evidence for neurological residual	Pathological fracture	Prednisone, Rituximab
6	extremely severe	21	Acetylsalicylic acid(+Enoxaparin)	+	+	+	+				Hemiparesis,ataxia and severe cognitive decline		Aspirin, Prednisone, IVIG (1 g/kg),MMF
7	Moderate	20	Acetylsalicylic acid	+	+	+	+	–			Mild cognitive decline		Aspirin, prednisone and IVIG (1 g/kg)

Note: N/A – not available; Abbreviations: CMV – cytomegalovirus, CPM – cyclophosphamid, IVMP – intravenous methylprednisolone, IVIG – intravenous immune globulin, MMF – mycophenolate mofetil, RTX - rituximab, SNHL - sensorineural hearing loss, VF – visual field

ISSN: 1471-2377